OverviewChartProfileKey statisticsFinancialsNews
Derivatives
TraderScreen

Synchrony Financial SYNCHRONY FIN.../  US87165B1035  /

London International
03/05/2024  14:12:53 Chg. - Volume Bid06:00:05 Ask06:00:05 Market Capitalization Dividend Y. P/E Ratio
45.00USD - 504,373
Turnover: 22.6 mill.		 -Bid Size: - -Ask Size: - 21.06 bill.USD 1.80% 10.23
TeleTrader 17/09 JPMorgan may allegedly become new Apple credit card issuer
GlobeNewswire 28/08 Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
GlobeNewswire 28/08 Unlock Even More Savings with Verizon Visa® Card
GlobeNewswire 21/08 PEOPLE and Great Place To Work Announce PEOPLE’s '100 Companies that Care' for 2024
GlobeNewswire 14/08 Katapult Grows Second Quarter Revenue 9% Year-Over-Year
GlobeNewswire 09/08 Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 09/08 Atlanticus Reports Second Quarter 2024 Financial Results
GlobeNewswire 30/07 Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragil...
GlobeNewswire 13/06 What Employees at the Fortune Best Workplaces in New York, Chicago, Texas, and the Bay Area Value Mo...
GlobeNewswire 11/06 Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patie...
GlobeNewswire 08/06 Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2...
GlobeNewswire 29/05 Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
GlobeNewswire 23/05 AI-Based Analysis of Dynamic Digital Radiography Data Gives Researchers Greater Insight into Lung Fu...
GlobeNewswire 15/05 Katapult Grows First Quarter Revenue 18% Year-Over-Year
GlobeNewswire 10/05 Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 08/05 Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference
GlobeNewswire 30/04 Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
GlobeNewswire 23/04 Leaders from Fortune 100 Best Companies to Work For To Share Insights at For All Summit May 7-9
GlobeNewswire 04/04 100 Best Companies to Work For in 2024 Deliver ‘Staggering’ Business Performance
GlobeNewswire 08/03 Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwr...
GlobeNewswire 07/03 Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenter...
GlobeNewswire 06/03 Akero Therapeutics Announces Pricing of Public Offering of Common Stock
GlobeNewswire 04/03 Akero Therapeutics Announces Proposed Public Offering of Common Stock
GlobeNewswire 04/03 Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2...
GlobeNewswire 29/02 Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efru...